Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by 
Fc-engineering of IgA antibody against the epidermal growth factor receptor

Rösner, T.; Kretschmer, A.; Lohse, S.; Meyer, S.; Jansen, J. H. M.; Möginger, Uwe; Sondermann, P.; Kolarich, Daniel; Leusen, J. H. W.; Valerius, T.

doi:10.1016/S0959-8049(16)33027-1

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

会議抄録

Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor

MPS-Authors

/persons/resource/persons121655

Möginger, Uwe
Daniel Kolarich, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121498

Kolarich, Daniel
Daniel Kolarich, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Rösner, T., Kretschmer, A., Lohse, S., Meyer, S., Jansen, J. H. M., Möginger, U., Sondermann, P., Kolarich, D., Leusen, J. H. W., & Valerius, T. (2016). Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor. European Journal of Cancer, 69:, S144.

引用: https://hdl.handle.net/11858/00-001M-0000-002C-4A60-B

要旨

要旨はありません